デキストラン硫酸ナトリウムを用いた直腸結腸切除術および回腸嚢肛門吻合後の嚢炎のラットモデル

Executive Industry Relevance

Establishing a reproducible rat model of pouchitis following proctocolectomy and ileal pouch-anal anastomosis (IPAA) addresses a critical gap in preclinical research for inflammatory bowel disease complications. This model enables mechanistic de-risking and target validation for therapeutic discovery in a disease-relevant system where clinical studies are limited. Its robust design supports translational continuity from early discovery through preclinical evaluation, informing portfolio decisions for novel anti-inflammatory agents.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables interrogation of pouchitis pathogenesis and immune-mediated mechanisms in a controlled in vivo context.
• Supports functional target validation by recapitulating human post-surgical inflammatory responses.
• Facilitates predictive confidence in candidate selection by providing a reproducible disease model.

Screening & Assay Development

• Provides a validated animal system for quantitative assessment of drug efficacy and biomarker response.
• Standardizes endpoints such as weight loss, food intake, and histopathology for cross-study comparability.
• Enables reproducible screening of anti-inflammatory compounds in a clinically relevant setting.

Translational & Preclinical Research

• Aligns with disease-relevant pathology, supporting translational biomarker discovery and validation.
• Bridges early mechanistic findings to preclinical proof-of-concept for pouchitis interventions.
• Reduces translational risk by modeling post-surgical inflammatory complications observed in UC patients.

Pipeline & Workflow Integration

This rat pouchitis model integrates into the discovery-to-preclinical continuum, enabling hypothesis testing, lead identification, and translational validation for anti-inflammatory therapeutics targeting post-colectomy complications.

• Discovery Biology: Supports mechanistic studies of immune and inflammatory pathways implicated in pouchitis.
• Screening: Delivers quantitative, reproducible outputs for compound efficacy and safety profiling.
• Analytics: Provides standardized readouts including weight, intake metrics, and tissue pathology for robust statistical analysis.
• Translational Research: Facilitates alignment of preclinical findings with clinical pouchitis pathology and biomarker profiles.
• Enterprise Reuse: Establishes a reusable platform for iterative drug and biomarker evaluation across discovery programs.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in pouchitis drug discovery.
• Operational Value: Enhances standardization, reproducibility, and scalability of preclinical inflammatory disease models.
• Strategic Value: Informs go/no-go decisions and optimizes resource allocation by de-risking early-stage candidates.
• Portfolio Impact: Enables risk-adjusted prioritization and advancement of anti-inflammatory assets targeting post-surgical complications.

Implementation Considerations

• Requires expertise in microsurgical techniques and post-operative animal care.
• Demands access to specialized instrumentation for IPAA surgery and DSS administration.
• Necessitates cross-team standardization of endpoints and analytical protocols.
• Adaptation may be needed for different rodent strains or pouchitis-inducing agents.
• Model limitations include surgical complexity and the need for rigorous post-operative monitoring.

Biopharma FAQs